Samsung Peptide publishes definitive tender offer result, holds 97.99% of PolyPeptide

Samsung Peptide, a subsidiary of Samsung Biologics, published the definitive end result of its public tender offer for PolyPeptide Group AG, revealing a 97.99% stake. The offer remains subject to outstanding regulatory approvals, with completion anticipated by end of 2026 or Q1 2027.

Detected & updated continuously · Source: Nebula